Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20374424 | 0.87 | ACKR3 (0.45) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL17271431 | 0.84 | CHRM2 (0.51) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL19928689 | 0.84 | ALDH1A1 (0.43) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL8242595 | 0.84 | USP2 (0.61) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL5883993 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL728912 | 0.83 | USP2 (0.49) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL5537001 | 0.83 | USP2 (0.49) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL39764 | 0.81 | ACKR3 (0.50) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL3215748 | 0.81 | USP2 (0.47) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 | |
| SCHEMBL3215755 | 0.81 | L3MBTL1 (0.49) | SMN1; SMN2USP2ACKR3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160318878-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| WO-2015089479-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089481-A2 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 2947/4885USP2 3352/4885ACKR3 2402/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 2732/4885USP2 3715/4885ACKR3 2165/4885 |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 2947/4885USP2 3352/4885ACKR3 2402/4885 |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 2732/4885USP2 3715/4885ACKR3 2165/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 2947/4885USP2 3352/4885ACKR3 2402/4885 |
| US-20160318878-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SMN1; SMN2 3085/4885USP2 3410/4885ACKR3 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.